Trawick International Is Pleased To Announce Our Partnership With AardvarkCompare

FAIRHOPE, Ala., May 5, 2020 /PRNewswire/ — Trawick International, provider of travel medical insurance, trip cancellation insurance, international student insurance, group insurance, and many other products designed specifically for those traveling, is honored or announce our partnership with travel insurance online comparison site AardvarkCompare.com.

AardvarkCompare brings world-class insurance to customers, so they can travel with confidence. Along with providing consumers with an easy to use website with tons of insurance options to choose from; Aardvark generously donates 10% of their profits to support Aardvark Kids of Heroes™ charity partners.

“We are honored to add Trawick to AardvarkCompare – Travel Insurance Marketplace. Trawick has a world-class reputation for service to its customers wherever they are in the world. Moreover, they are an innovator. The new Trawick Voyager travel insurance policy, which is launched with AardvarkCompare, has industry-leading Cancel for Any Reason and Medical Waiver benefits. Insurance is built on trust, and shared values. We welcome Trawick as part of our family.”

Trawick International is based in Fairhope, Alabama, and was founded in 1998. Today we offer a variety of international travel insurance, trip cancellation/interruption, and student insurance plans.  We continue to research ground-breaking products and ideas which meet the needs of travelers everywhere.  Trawick strives to offer plans that not only meet those needs but exceed the expectations of our clients.

Today we are pleased to offer a variety of International travel insurance, trip cancellation/interruption, and student insurance plans.  We continue to research ground-breaking products and ideas which meet the needs of travelers everywhere.  Trawick strives to offer plans that not only meet those needs but exceed the expectations of our clients.

“We are excited to be partnering with AardvarkCompare.com,” said Daryl Trawick owner of Trawick International. “Traveling can be impacted by the unexpected, forcing travelers to cancel or interrupt their trips and incur unplanned expenses. Now more than ever travelers have the need for protecting the value of their trip cost along with protecting unexpected costs that can arise while traveling either domestically or internationally. Our plans are designed to protect these expenses that could affect your travels, such as trip cancellations or interruptions, travel delays, medical expenses, evacuations, and more.”

Contact: Daryl Trawick, 251-458-1799, dtrawick@trawickinternational.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/trawick-international-is-pleased-to-announce-our-partnership-with-aardvarkcompare-301050372.html

SOURCE Trawick International

Staff

Recent Posts

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE:…

2 hours ago

Akanda Corporation Announces Completion of F-3 Shelf Registration Statement

London, United Kingdom--(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or…

2 hours ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today…

3 hours ago

Justera Health Signs LOI to Acquire Popular Cannabis Brand Port North

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink:…

3 hours ago

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the…

3 hours ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production…

3 hours ago